Charles River Laboratories International Inc. (CRL) financial statements: income statement, balance sheet and cash flow
Charles River Laboratories International Inc.'s income statement, balance sheet and cash flow statement as filed with the SEC (10-K and 10-Q), with the latest fiscal years and quarters. In its latest fiscal year (Dec 27, 2025 · FY), Charles River Laboratories International Inc. reported revenue of $4.0B (-0.9% year on year) and net income of ($144.3M) (-750.1% year on year).
Income statement
Charles River Laboratories International Inc. income statement, fiscal years
Line item
Dec 27, 2025 · FY
Dec 28, 2024 · FY
Dec 30, 2023 · FY
Dec 31, 2022 · FY
Total revenue
$4.0B
$4.0B
$4.1B
$4.0B
Cost of revenue (excluding amortization of intangible assets)
$2.7B
$2.7B
$2.6B
$2.5B
Selling, general and administrative
$743.1M
$751.0M
$747.9M
$665.1M
Amortization of intangible assets
$179.1M
$138.5M
$137.4M
$146.6M
Intangible asset impairment
$211.0M
—
—
—
Goodwill impairment
$165.0M
$215.0M
—
—
Operating income
$25.2M
$227.3M
$617.3M
$651.0M
Interest income
$4.9M
$8.6M
$5.2M
$780.0K
Interest expense
($107.0M)
($126.3M)
($136.7M)
($59.3M)
Other income (expense), net
($22.6M)
($16.5M)
$95.5M
$30.5M
Income (loss) before income taxes
($99.5M)
$93.1M
$581.3M
—
Provision for income taxes
$42.7M
$67.8M
$100.9M
$130.4M
Net income (loss)
($142.2M)
$25.3M
$480.4M
$492.6M
Less: Net income attributable to noncontrolling interests
$2.2M
$3.1M
$5.7M
$6.4M
Net income (loss) attributable to Charles River Laboratories International, Inc.
($144.3M)
$22.2M
$474.6M
$486.2M
Less: Incremental dividends attributed to noncontrolling interest holders
$0
$11.9M
—
—
Net income (loss) available to Charles River Laboratories International, Inc. common shareholders
($144.3M)
$10.3M
—
—
Basic (in dollars per share)
-$2.91
$0.20
$9.27
$9.57
Diluted (in dollars per share)
-$2.91
$0.20
$9.22
$9.48
Basic (in shares)
49.6M
51.4M
51.2M
50.8M
Diluted (in shares)
49.6M
51.6M
51.5M
51.3M
Charles River Laboratories International Inc. income statement, quarters
Line item
Jun 27, 2026 · Q2
Mar 28, 2026 · Q1
Sep 27, 2025 · Q3
Jun 28, 2025 · Q2
Total revenue
$1.0B
$995.8M
$1.0B
$1.0B
Cost of revenue (excluding amortization of intangible assets)
$640.7M
$701.2M
$666.1M
$675.1M
Selling, general and administrative
$228.9M
$159.4M
$177.6M
$191.5M
Amortization of intangible assets
$14.6M
$15.3M
$27.4M
$65.4M
Operating income
$119.9M
$119.9M
$133.8M
$100.1M
Interest income
$1.0M
$1.0M
$1.4M
$1.1M
Interest expense
($30.3M)
($26.7M)
($25.4M)
($30.0M)
Other (expense) income, net
($37.4M)
($124.1M)
($22.6M)
$154.0K
Income before income taxes
$53.2M
($29.9M)
$87.2M
$71.4M
Provision for income taxes
$53.9M
($15.1M)
$31.6M
$18.7M
Net income (loss)
($760.0K)
($14.8M)
$55.6M
$52.7M
Less: Net income attributable to noncontrolling interests
$722.0K
$41.0K
$1.1M
$367.0K
Net income (loss) attributable to common shareholders
($1.5M)
($14.8M)
$54.4M
$52.3M
Basic (in dollars per share)
-$0.03
-$0.30
$1.11
$1.06
Diluted (in dollars per share)
-$0.03
-$0.30
$1.10
$1.06
Basic (in shares)
48.0M
49.0M
49.2M
49.1M
Diluted (in shares)
48.0M
49.0M
49.4M
49.3M
Balance sheet
Charles River Laboratories International Inc. balance sheet, fiscal years
Line item
Dec 27, 2025 · FY
Dec 28, 2024 · FY
Dec 30, 2023 · FY
Dec 31, 2022 · FY
Cash and cash equivalents
$213.8M
$194.6M
$276.8M
$233.9M
Trade receivables and contract assets, net of allowances for credit losses of $10,463 and $18,301, respectively
$708.9M
$720.9M
$780.4M
$752.4M
Inventories
$299.1M
$278.5M
$380.3M
$255.8M
Prepaid assets
$96.1M
$103.2M
$87.9M
$89.3M
Other current assets
$129.2M
$105.8M
$83.4M
$107.6M
Total current assets
$1.4B
$1.4B
$1.6B
$1.4B
Property, plant and equipment, net
$1.7B
$1.6B
$1.6B
$1.5B
Venture capital and strategic equity investments
$207.0M
$218.3M
$243.8M
$311.6M
Operating lease right-of-use assets, net
$361.4M
$412.5M
$394.0M
$391.8M
Goodwill
$2.8B
$2.8B
$3.1B
$2.8B
Intangible assets, net
$340.0M
$723.4M
$864.1M
$955.3M
Deferred tax assets
$67.3M
$42.2M
$40.3M
$41.3M
Other assets
$293.2M
$278.2M
$309.4M
$148.3M
Total assets
$7.1B
$7.5B
$8.2B
$7.6B
Accounts payable
$148.8M
$140.3M
$168.9M
$205.9M
Accrued compensation
$268.9M
$179.4M
$213.3M
$197.1M
Deferred revenue
$210.4M
$248.3M
$241.8M
$264.3M
Accrued liabilities
$270.1M
$232.0M
$227.8M
$219.8M
Other current liabilities
$222.2M
$194.0M
$203.2M
$204.6M
Total current liabilities
$1.1B
$994.1M
$1.1B
$1.1B
Long-term debt, net and finance leases
$2.1B
$2.2B
$2.6B
$2.7B
Operating lease right-of-use liabilities
$434.0M
$483.8M
$419.2M
$389.7M
Deferred tax liabilities
$95.2M
$107.0M
$191.3M
$215.6M
Other long-term liabilities
$138.3M
$195.2M
$223.2M
$174.8M
Total liabilities
$3.9B
$4.0B
$4.5B
$4.6B
Redeemable noncontrolling interests
$41.3M
$41.1M
$56.7M
$42.4M
Preferred stock, $0.01 par value; 20,000 shares authorized; no shares issued and outstanding
0
0
0
0
Common stock, $0.01 par value; 120,000 shares authorized; 49,217 shares issued and outstanding as of December 27, 2025 and 51,141 shares issued and outstanding as of December 28, 2024
492.0K
511.0K
513.0K
509.0K
Additional paid-in capital
$1.9B
$2.0B
$1.9B
$1.8B
Retained earnings
$1.4B
$1.8B
$1.9B
$1.4B
Treasury stock, at cost, zero shares as of December 27, 2025 and December 28, 2024
0
0
0
0
Accumulated other comprehensive loss
($171.8M)
($317.3M)
($196.4M)
($262.1M)
Total Charles River Laboratories International, Inc. equity
$3.2B
$3.5B
$3.6B
$3.0B
Nonredeemable noncontrolling interest
$5.3M
$5.4M
$5.4M
$4.8M
Total equity
$3.2B
$3.5B
$3.6B
$3.0B
Total liabilities, redeemable noncontrolling interests and equity
$7.1B
$7.5B
$8.2B
$7.6B
Charles River Laboratories International Inc. balance sheet, quarters
Line item
Jun 27, 2026
Mar 28, 2026
Sep 27, 2025
Jun 28, 2025
Cash and cash equivalents
$192.0M
$191.8M
$207.1M
$182.8M
Trade receivables and contract assets, net of allowances for credit losses of $8,715 and $10,463, respectively
$711.8M
$700.3M
$734.5M
$767.6M
Inventories
$346.3M
$359.7M
$302.6M
$279.6M
Prepaid assets
$100.4M
$102.1M
$121.5M
$110.0M
Other current assets
$178.7M
$134.9M
$166.4M
$129.9M
Total current assets
$1.5B
$1.5B
$1.5B
$1.5B
Property, plant and equipment, net
$1.5B
$1.5B
$1.6B
$1.6B
Venture capital and strategic equity investments
$206.5M
$209.7M
$194.6M
$216.1M
Operating lease right-of-use assets, net
$330.2M
$317.8M
$374.3M
$385.8M
Goodwill
$3.1B
$3.0B
$2.9B
$2.9B
Intangible assets, net
$253.2M
$249.0M
$571.1M
$602.5M
Deferred tax assets
$53.8M
$88.6M
$36.9M
$46.9M
Other assets
$587.6M
$826.2M
$290.9M
$296.5M
Total assets
$7.5B
$7.7B
$7.5B
$7.6B
Accounts payable
$141.0M
$134.0M
$169.6M
$145.8M
Accrued compensation
$187.8M
$166.9M
$269.7M
$227.5M
Deferred revenue
$203.0M
$194.3M
$237.7M
$268.3M
Accrued liabilities
$380.1M
$372.4M
$228.9M
$231.6M
Other current liabilities
$222.8M
$226.1M
$216.0M
$207.2M
Total current liabilities
$1.1B
$1.1B
$1.1B
$1.1B
Long-term debt, net and finance leases
$2.6B
$2.7B
$2.2B
$2.3B
Operating lease right-of-use liabilities
$407.7M
$393.1M
$443.2M
$453.7M
Deferred tax liabilities
$78.7M
$81.4M
$123.0M
$109.3M
Other long-term liabilities
$402.5M
$510.6M
$189.5M
$185.2M
Total liabilities
$4.6B
$4.7B
$4.1B
$4.2B
Redeemable noncontrolling interests
$42.5M
$41.9M
$40.5M
$40.0M
Preferred stock, $0.01 par value; 20,000 shares authorized; no shares issued and outstanding
0
0
0
0
Common stock, $0.01 par value; 120,000 shares authorized; 49,550 shares issued and 47,728 shares outstanding as of June 27, 2026, and 49,217 shares issued and outstanding as of December 27, 2025
496.0K
493.0K
514.0K
513.0K
Additional paid-in capital
$2.0B
$2.0B
$2.0B
$2.0B
Retained earnings
$1.4B
$1.4B
$1.9B
$1.9B
Treasury stock, at cost, 1,822 and zero shares, as of June 27, 2026 and December 27, 2025, respectively
-323.2M
-210.0M
-363.4M
-363.3M
Accumulated other comprehensive loss
($196.0M)
($191.0M)
($191.6M)
($166.5M)
Total Charles River Laboratories International, Inc. equity
$2.8B
$2.9B
$3.4B
$3.4B
Nonredeemable noncontrolling interest
$6.4M
$5.8M
$4.9M
$6.3M
Total equity
$2.8B
$2.9B
$3.4B
$3.4B
Total liabilities, redeemable noncontrolling interests and equity
$7.5B
$7.7B
$7.5B
$7.6B
Cash flow statement
Charles River Laboratories International Inc. cash flow statement, fiscal years
Line item
Dec 27, 2025 · FY
Dec 28, 2024 · FY
Dec 30, 2023 · FY
Dec 31, 2022 · FY
Net income (loss)
($142.2M)
$25.3M
$480.4M
$492.6M
Depreciation and amortization
$403.3M
$361.7M
$314.1M
$303.9M
Goodwill impairment
$165.0M
$215.0M
—
—
Long-lived asset impairments
$259.1M
$51.8M
$41.9M
—
Stock-based compensation
$71.1M
$69.9M
$72.0M
$73.6M
Deferred income taxes
($75.3M)
($67.4M)
($50.9M)
($35.9M)
Write down of inventories
$12.4M
$47.0M
—
—
(Gains) losses and impairments on venture capital and strategic equity investments, net
$24.9M
—
—
—
Provision for credit losses
$6.1M
$14.8M
$18.2M
$6.7M
(Gain) loss on divestitures, net
($3.4M)
$659.0K
$961.0K
($123.4M)
Other, net
$2.5M
$33.3M
$1.6M
$27.5M
Trade receivables and contract assets, net
$35.7M
$21.6M
($33.4M)
($150.6M)
Inventories
($48.8M)
$16.8M
($62.3M)
($78.5M)
Accounts payable
$2.9M
($14.3M)
($20.4M)
($2.7M)
Accrued compensation
$79.3M
($27.6M)
$12.4M
($42.2M)
Deferred revenue
($38.1M)
$18.5M
($21.7M)
$57.7M
Customer contract deposits
$14.7M
$6.6M
($15.6M)
$30.5M
Other assets and liabilities, net
($31.6M)
($52.0M)
$38.6M
$33.2M
Net cash provided by operating activities
$737.6M
$734.6M
$683.9M
$619.6M
Capital expenditures
($219.2M)
($233.0M)
($318.5M)
($324.7M)
Purchases of investments and contributions to venture capital investments
($20.1M)
($52.9M)
($54.2M)
($158.3M)
Acquisition of businesses and assets, net of cash acquired
$0
($5.5M)
($194.8M)
($283.4M)
Proceeds from sale of investments
$9.1M
$41.7M
$6.7M
$4.5M
Proceeds from sale of businesses, net
$17.4M
$0
$0
—
Other, net
$3.4M
$4.5M
($2.3M)
($9.3M)
Net cash used in investing activities
($209.3M)
($245.1M)
($563.2M)
($607.9M)
Proceeds from long-term debt and revolving credit facility
$1.2B
$1.1B
$776.4M
$3.0B
Payments on long-term debt, revolving credit facility, and finance lease obligations
($1.3B)
($1.5B)
($851.7M)
($2.9B)
Proceeds from exercises of stock options
$714.0K
$23.9M
$25.6M
$25.1M
Purchase of treasury stock
($360.7M)
($119.2M)
($24.2M)
($38.7M)
Payments of contingent consideration
($21.8M)
$0
($2.7M)
($10.4M)
Purchase of remaining equity interests of other redeemable noncontrolling interest
($19.1M)
($12.0M)
($4.8M)
($30.5M)
Other, net
($14.0M)
($31.4M)
($4.1M)
($7.8M)
Net cash used in financing activities
($536.7M)
($550.9M)
($85.5M)
($42.4M)
Effect of exchange rate changes on cash, cash equivalents, and restricted cash
$18.8M
($17.5M)
$8.0M
$25.6M
Net change in cash, cash equivalents, and restricted cash
$10.4M
($78.9M)
$43.3M
($5.1M)
Cash, cash equivalents, and restricted cash, beginning of period
$205.6M
$284.5M
$241.2M
$246.3M
Cash, cash equivalents, and restricted cash, end of period
$216.0M
$205.6M
$284.5M
$241.2M
Charles River Laboratories International Inc. cash flow statement, quarters
Line item
Jun 27, 2026 · YTD
Mar 28, 2026 · Q1
Sep 27, 2025 · YTD
Jun 28, 2025 · YTD
Net income (loss)
($15.6M)
($14.8M)
$134.1M
$78.6M
Depreciation and amortization
$134.4M
$67.2M
$325.0M
$239.9M
Long-lived asset impairments
$26.3M
$15.9M
$36.2M
$31.2M
Stock-based compensation
$42.2M
$22.4M
$53.5M
$30.2M
Deferred income taxes
$12.1M
($29.4M)
($15.1M)
($41.0M)
Write down of inventories
$3.2M
$1.5M
$10.7M
$11.1M
(Gains) losses and impairments on venture capital and strategic equity investments, net
($6.9M)
$1.1M
$34.0M
—
Gain on sale of assets
($38.5M)
—
—
—
Provision for credit losses
$1.1M
$47.0K
$4.6M
$2.2M
(Gain) loss on divestitures, net
$181.4M
$118.0M
($3.4M)
($3.4M)
Other, net
($12.6M)
($34.7M)
$3.3M
$2.3M
Trade receivables and contract assets, net
($87.1M)
($65.3M)
$8.1M
($18.5M)
Inventories
$43.7M
$26.0M
($45.3M)
($14.0M)
Accounts payable
$21.3M
$20.5M
$40.7M
$16.2M
Accrued compensation
($64.9M)
($83.8M)
$81.9M
$39.0M
Deferred revenue
$5.6M
$5.2M
($12.3M)
$11.3M
Customer contract deposits
($4.5M)
($135.0K)
($533.0K)
$568.0K
Other assets and liabilities, net
($20.3M)
($8.5M)
($65.3M)
($22.2M)
Net cash provided by operating activities
$220.8M
$41.1M
$590.1M
$376.3M
Acquisition of businesses and assets, net of cash acquired
($467.3M)
($405.0M)
$0
$0
Capital expenditures
($87.0M)
($55.9M)
($130.2M)
($94.6M)
Purchases of investments and contributions to venture capital investments
($11.8M)
($8.5M)
($12.5M)
($8.1M)
Proceeds from sale of investments
$11.1M
$2.9M
$5.6M
$2.1M
Proceeds from sale of businesses and assets, net
$176.6M
$60.1M
$17.4M
$17.4M
Other, net
($1.3M)
($1.5M)
$3.2M
$347.0K
Net cash used in investing activities
($379.7M)
($407.8M)
($116.5M)
($82.8M)
Proceeds from long-term debt and revolving credit facility
$1.3B
$912.5M
$1.1B
$963.4M
Payments on long-term debt, revolving credit facility, and finance lease obligations
($745.9M)
($355.7M)
($1.1B)
($887.7M)
Proceeds from exercises of stock options
$1.6M
$1.2M
$3.0K
$1.0K
Purchase of treasury stock
($323.9M)
($208.3M)
($360.6M)
($360.5M)
Payments of contingent consideration
($11.4M)
—
($21.8M)
($21.8M)
Purchase of remaining equity interests of other redeemable noncontrolling interest
$0
$0
($19.1M)
($19.1M)
Other, net
($2.6M)
($2.0M)
($12.7M)
($6.5M)
Net cash provided by (used in) financing activities
$183.1M
$347.7M
($484.9M)
($332.2M)
Effect of exchange rate changes on cash, cash equivalents, and restricted cash
$467.0K
$1.2M
$14.9M
$17.9M
Net change in cash, cash equivalents, and restricted cash
$24.6M
($17.8M)
$3.6M
($20.8M)
Cash, cash equivalents, and restricted cash, beginning of period
$216.0M
$216.0M
$205.6M
$205.6M
Cash, cash equivalents, and restricted cash, end of period